B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression
Advanced Science · 2026
DOI: 10.1002/advs.202511293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Shaoqin Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, N-Acetylgalactosaminyltransferases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Natural Sciences Foundation, National Science Foundation of China, innovation of Science and Technology, Fujian province.
Abstract (Originalsprache)
Abnormal glycosylation is a hallmark of cancer cells and plays a crucial role in tumor invasion and metastasis. However, the relationship between glycogenes and prostate cancer (PCa) remains poorly understood. This study aims to identify glycogenes involved in the onset and progression of PCa and to investigate the molecular mechanisms underlying their role. By integrating RNA‐seq data from multiple clinical cohorts (TCGA and CPGEA) and performing biochemical validation, we identified beta‐1,4‐N‐acetylgalactosaminyltransferase 4 (B4GALNT4) as a glycogene significantly associated with advanced pathological stages, higher Gleason scores, and poor prognosis in PCa patients. Furthermore, multivariate Cox regression analysis confirmed B4GALNT4 as an independent prognostic factor for survival. Mechanistically, we discovered that B4GALNT4 interacts with PDK1 and glycosylates it at residue N531. This N‐glycosylation stabilizes PDK1 by blocking its degradation, thereby activating the PI3K‐AKT signaling pathway. This signaling axis promotes PCa cell proliferation, migration, and invasion in vitro. Moreover, B4GALNT4 knockdown suppresses tumor growth in xenograft models and correlates with decreased PDK1 and p‐AKT levels in vivo. Our findings establish B4GALNT4 as a critical regulator of PCa progression through PDK1 glycosylation and PI3K‐AKT activation, suggesting that B4GALNT4 serves as both a prognostic biomarker and a potential therapeutic target for PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, China.
- Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
ORCID-Profile: Xu Gao
Förderung
- Fujian Natural Sciences Foundation
- National Science Foundation of China
- innovation of Science and Technology, Fujian province
- National Natural Science Foundation of China
Zitieren
APA
Jiang, S., Li, M., Su, Q., Dou, R., Lin, S., Zhang, J., Sun, X., Yu, H., Bao, W., Qu, M., Wang, Y., Yang, C., & Gao, X. (2026). B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression. Advanced Science. https://doi.org/10.1002/advs.202511293
Vancouver
Jiang S, Li M, Su Q, Dou R, Lin S, Zhang J, et al. B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression. Advanced Science. 2026. doi:10.1002/advs.202511293
BibTeX
@article{Jiang2026,
author = {Jiang, Shaoqin and Li, Mengqiang and Su, Qingfu and Dou, Ruiling and Lin, Shaoshan and Zhang, Jili and Sun, Xiaochen and Yu, Haolan and Bao, Wei and Qu, Min and Wang, Yan and Yang, Chenghua and Gao, Xu},
title = {B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202511293}
}
EUVIMED